Docs discuss sluggish switch to Humira biosimilars, name preferred off-patent options
Spherix Global Insights looked at which biosimilar brands stand to benefit as AbbVie loses access. (AbbVie) AbbVie reported global Humira sales of $2.8 billion in the second quarter. That represented a 29% drop on an operational basis but meant Humira remained a major product more than one year on from the launch of the first biosimilar in […]
Despite Projections of a 2024 Adalimumab Biosimilar Boom, Humira Remains Dominant for Now, According to Spherix Global Insights
US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 rheumatologists, and 106 dermatologists), to provide an updated perspective on adalimumab biosimilar […]
Lupus landscape ‘poised for evolution’ as US doctors eagerly await new entrants
Biogen’s litifilimab “stands out as an especially strong competitor” to Benlysta and Saphnelo, according to Spherix Global Insights analysts. New biologics such as GSK’s Benlysta and AstraZeneca’s Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus (SLE) treatment for many years. However, the landscape may be about to change with the […]
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
While reported use of Sanofi/Regeneron’s Dupixent has declined with the adoption of LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments is on the rise, according to Spherix Global Insights. EXTON, PA., September 9, 2024 — Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s […]
Roche and Regeneron Square Off in Lucrative Eye Disease Market
Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial growth A therapy market, as healthcare providers and patients switch from older products. The competition between Roche and Regeneron to dominate the ophthalmology market is heating up. With their successful launches of anti-vascular endothelial growth factor A (VEGF-A) drugs […]
Ipsen’s Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead’s Livdelzi
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as their preferred asset. Exton, PA., August 28, 2024 – – The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of […]
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising Advances in Gene Therapies
New research conducted by Spherix Global Insights highlights opportunities for genetic therapies (Casgevy, Lyfgenia, Zynteglo) and emerging pipeline agents (including mitapivat, etavopivat, inclacumab and others). Exton, PA – August 28, 2024 – Despite advancements in treatments, sickle cell disease and thalassemia continue to present significant challenges for patients and healthcare providers. These genetic disorders disrupt […]
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline candidates for prescription if approved. Exton, PA., July 24, 2024 – The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking advancements in gene therapy for retinal disorders. […]
Evaluating the Efficacy and Perception of HS Treatment Options
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing hidradenitis suppurativa (HS) effectively remains challenging for dermatology clinicians, necessitating innovative and effective treatment options. Recently, Spherix Global Insights took a deep dive into secukinumab (Cosentyx; Novartis) versus adalimumab (Humira; AbbVie) in HS treatment performance.1 […]
Conflicting Views Between Epileptologists and General Neurologists Hinder Adoption of New Refractory Epilepsy Treatments
New brands aiming to enter the refractory epilepsy market may face challenges achieving desired penetration without improved general neurologist education efforts, according to Spherix Global Insights. EXTON, PA., July 8, 2024 – Chronic epilepsy is often well managed by neurologists, but a sizable proportion of adults with epilepsy continue to experience seizures at varying frequencies […]
